Cyprus/Greece/MaltaCyprusGreeceMalta

EU orders to lift GMO ban

17.03.2006

Athens/Brussels - The European Commission has decided that the Greek national ban of MON810 maize is not properly justified and has therefore ordered to lift the ban. Up to now, Greece had referred to the safeguard clause for protection of its population against potential risks for health or environment thought to be associated with the GM crops. But it did not provide any new scientific evidence that could change the current safety assessments. MON810 is one of 18 genetically modified organisms (GMOs) currently authorized for planting in the EU. If Greece fails to act, it may be taken to the European Court of Justice. According to environmental organizations Monsanto has not provided the Commission with an adequate plan to monitor the general environmental impact of MON810.

Cyprus/Greece/MaltaCyprusGreeceMalta

10.12.2011

Athens – Greek researchers have called on members of the international research community to sensitise their governments to the problems in their country’s research landscape. “The orderly execution of the badly needed reforms...

Cyprus/Greece/MaltaCyprusGreeceMalta

01.10.2011

Athens – The supply of innovative bio­pharmaceuticals to Greek hospitals has broken down. Swiss Roche AG has pulled the plug by stopping delivery of drugs for cancer and other diseases to some state-funded hospitals. Among them...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.06.2011

Athens – The situation in the pharmaceutical market in Greece increasingly looks to be spiralling out of control. According to the Financial Times, the Greek government already appears to be unable to pay healthcare companies...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.07.2010

Athens – The Novo Nordisk Group has restarted sales of its insulin products in Greece. At the beginning of June, the Danish pharmaceutical company had pulled out 17 products – mostly insulin or insulin analogues – after the Greek...

Cyprus/Greece/MaltaCyprusGreeceMalta

11.03.2010

Athens – A EUR2.5m EU research project targeting olfaction in the malaria carrier Anopheles gambiae is to be coordinated by Greek researchers from the Institute of Bio­logy at the Demokritos National Centre of Scientific Research...

Cyprus/Greece/Malta, PolandCyprusGreeceMalta

29.04.2009

Nicosia – Golgi Pharmaceuticals Ltd is strengthening its collaboration with London-based ReGen Therapeutics. The Cypriot firm will produce and package Colostrinin tablets, and expand distribution to Greece and other Balkan...

Cyprus/Greece/MaltaCyprusGreeceMalta

29.04.2009

Athens –The 5th International Biotechnology Forum (IGBF5), which is to be held May 8-9 in Athens, boasts appearances by three Nobel Prize winners. Andrew Schally, Richard Roberts and Sir Peter Mansfield will speak at the opening...

Cyprus/Greece/MaltaCyprusGreeceMalta

16.04.2009

Golgi Pharmaceuticals of Cyprus is strengthening its collaboration with London-based ReGen Therapeutics. Golgi will produce tablets of and package Colostrinin, and expand distribution to Greece and other Balcan countries....

Cyprus/Greece/MaltaCyprusGreeceMalta

03.11.2008

Athens/Houston – Greece is planning to establish state-of-the-art clinics for stem cell therapy with associated stem cell banks. In mid-August, GloCal Investment Ventures Enterprise (G.I.V.E.) – a venture capital fund backed by...

Cyprus/Greece/MaltaCyprusGreeceMalta

18.08.2008

Athens – Greek diagnostics supplier Neo­medica has entered into a distribution agreement with Swedish Life Assays AB (Lund), a daughter of Chemel AB. Neo­medica, a specialist for point-of care tests, now has exclusive rights to...

Displaying results 1 to 10 out of 47

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-cyprus-greece-malta/article/eu-orders-to-lift-gmo-ban.html

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR349.3%
  • SANTHERA (CH)69.50 CHF114.8%
  • ADDEX (CH)4.21 CHF92.2%

FLOP

  • MERCK KGAA (D)63.45 EUR-51.0%
  • THROMBOGENICS (B)8.55 EUR-47.3%
  • VERONA PHARMA (UK)1.12 GBP-46.2%

TOP

  • SANTHERA (CH)69.50 CHF3410.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.5%

No liability assumed, Date: 21.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events